Long-term outcomes of two-dose alemtuzumab induction in pediatric kidney transplantation

IF 1.2 4区医学 Q3 PEDIATRICS

Pediatric Transplantation Pub Date : 2024-04-16 DOI:10.1111/petr.14753

Rachel M. Engen, Sharon M. Bartosh

引用次数: 0

Abstract

Alemtuzumab is a lymphocyte depleting agent used for induction in kidney transplant, but long-term information on its use in pediatric recipients remains sparse.

Abstract Image

查看原文本刊更多论文

小儿肾移植中两剂阿仑妥珠单抗诱导疗法的长期疗效

阿来珠单抗是一种用于肾移植诱导的淋巴细胞耗竭剂，但有关其在儿童受者中长期应用的信息仍然很少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Transplantation 医学-小儿科

CiteScore

2.90

自引率

15.40%

发文量

216

审稿时长

3-8 weeks

期刊介绍： The aim of Pediatric Transplantation is to publish original articles of the highest quality on clinical experience and basic research in transplantation of tissues and solid organs in infants, children and adolescents. The journal seeks to disseminate the latest information widely to all individuals involved in kidney, liver, heart, lung, intestine and stem cell (bone-marrow) transplantation. In addition, the journal publishes focused reviews on topics relevant to pediatric transplantation as well as timely editorial comment on controversial issues.